Skip to main content

Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US”

A Letter to the Editor to this article was published on 09 November 2020

The Original Article was published on 12 June 2020

This is a preview of subscription content, access via your institution.


  1. 1.

    Padula WV, Parasrampuria S, Socal MP, et al. Market exclusivity for drugs with multiple orphan approvals (1983–2017) and associated budget impact in the US. PharmacoEconomics. 2020;38:1115–21.

    Article  PubMed  Google Scholar 

  2. 2.

    Lichenberg FR, Waldfogel J. Does misery love company? Evidence from pharmaceutical markets before and after the Orphan Drug Act. NBER Working Paper No. 9750, June 2003. 2003. Accessed 29 Oct 2020.

  3. 3.

    Reaves ND. A model of effective health policy. J Health Soc Policy. 2003;17(4):61–71.

    Article  PubMed  Google Scholar 

  4. 4.

    Manning R, Stomberg C, Scher B, Twigg K, Huson A. Similar products at different prices: can biopharmaceutical companies segment markets? Int J Econ Bus. 2015;22(2):231–43.

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Richard Manning.

Ethics declarations



Conflict of Interest

Richard Manning is a consultant to several clients with interests in healthcare, including law firms, government agencies, branded and generic/biosimilar biopharmaceutical manufacturers, health insurers, and trade organizations.

Ethics Approval

Not applicable.

Consent to Participate

Not applicable.

Consent for Publication

Not applicable.

Data Availability and Material

Not applicable.

Code Availability

Not applicable.

Author Contributions

Not applicable.

Additional information

This is the comment to the original article available at

The reply to this letter is available at

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Manning, R. Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US”. PharmacoEconomics 38, 1373–1374 (2020).

Download citation